NIKKEI 225
38,814.56 +94.06 (+0.24%) HANG SENG
17,941.78 -170.82 (-0.94%) CRUDE OIL
78.41 -0.04 (-0.05%) GOLD FUTURES
2,346.20 -2.90 (-0.12%) DOW
38,589.16 -57.94 (-0.15%) Bitcoin GBP
52,492.39 +428.52 (+0.82%)
APLS Jul 2024 35.000 put
| Previous close | 0.9000 |
| Open | 0.7500 |
| Bid | 0.6500 |
| Ask | 1.0500 |
| Strike | 35.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.7500 - 0.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 45 |
ZacksApellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
GlobeNewswireSYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that SYFOVRE® (pegcetacoplan injection) preserved visual function at 36 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). These positive data from the GALE long-term ext
ZacksWhy Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
